Genetic Inventory vs Non Current Assets Total Analysis
GENE Stock | USD 2.28 0.01 0.44% |
Genetic Technologies financial indicator trend analysis is much more than just examining Genetic Technologies latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genetic Technologies is a good investment. Please check the relationship between Genetic Technologies Inventory and its Non Current Assets Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.
Inventory vs Non Current Assets Total
Inventory vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genetic Technologies Inventory account and Non Current Assets Total. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Genetic Technologies' Inventory and Non Current Assets Total is 0.18. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Genetic Technologies, assuming nothing else is changed. The correlation between historical values of Genetic Technologies' Inventory and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Genetic Technologies are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Inventory i.e., Genetic Technologies' Inventory and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.18 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Inventory
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Genetic Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genetic Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 9.1 M, whereas Selling General Administrative is forecasted to decline to about 4.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 578.7K | 676.6K | 778.1K | 472.1K | Interest Income | 36.3K | 220.2K | 253.2K | 265.8K |
Genetic Technologies fundamental ratios Correlations
Click cells to compare fundamentals
Genetic Technologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Genetic Technologies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.6M | 23.0M | 20.8M | 14.9M | 13.4M | 14.4M | |
Other Current Liab | 806.5K | 955.5K | 1.6M | 1.3M | 1.2M | 989.0K | |
Total Current Liabilities | 1.4M | 1.4M | 3.8M | 3.3M | 3.0M | 2.0M | |
Total Stockholder Equity | 13.0M | 21.5M | 16.4M | 11.2M | 10.0M | 12.0M | |
Property Plant And Equipment Net | 440.2K | 637.7K | 953.3K | 599.2K | 539.3K | 863.9K | |
Net Debt | (13.7M) | (20.7M) | (11.1M) | (7.3M) | (6.6M) | (6.9M) | |
Retained Earnings | (135.9M) | (143.1M) | (150.2M) | (156.7M) | (141.0M) | (134.0M) | |
Cash | 14.2M | 20.9M | 11.7M | 7.9M | 9.0M | 9.8M | |
Non Current Assets Total | 440.2K | 735.6K | 6.1M | 4.4M | 3.9M | 5.9M | |
Non Currrent Assets Other | (440.2K) | 97.9K | (6.1M) | (4.2M) | (3.8M) | (3.6M) | |
Cash And Short Term Investments | 14.2M | 20.9M | 11.7M | 7.9M | 9.0M | 9.9M | |
Net Receivables | 789.4K | 1.1M | 2.4M | 1.9M | 2.2M | 2.3M | |
Common Stock Total Equity | 122.4M | 125.5M | 140.1M | 153.6M | 176.6M | 89.1M | |
Common Stock Shares Outstanding | 41.6M | 85.4M | 92.2M | 101.4M | 116.6M | 122.4M | |
Liabilities And Stockholders Equity | 15.6M | 23.0M | 20.8M | 14.9M | 13.4M | 14.4M | |
Inventory | 91.4K | 76.9K | 398.2K | 325.9K | 293.3K | 479.5K | |
Other Stockholder Equity | 13.0M | 162.0M | 11.5M | 6.5M | 7.5M | 7.1M | |
Total Liab | 2.6M | 1.4M | 4.4M | 3.7M | 3.3M | 2.3M | |
Property Plant And Equipment Gross | 440.2K | 637.7K | 1.9M | 1.8M | 1.6M | 913.1K | |
Total Current Assets | 15.2M | 22.2M | 14.7M | 10.5M | 12.1M | 11.7M | |
Common Stock | 140.1M | 153.6M | 155.1M | 161.3M | 185.5M | 95.3M | |
Short Long Term Debt Total | 481.8K | 204.0K | 652.5K | 532.8K | 479.6K | 402.1K | |
Other Current Assets | 97.8K | 1.9K | 18.2K | 17.4K | 15.7K | 14.9K | |
Short Term Debt | 240.9K | 179.6K | 264.1K | 303.6K | 273.2K | 286.9K | |
Accounts Payable | 350.2K | 269.7K | 1.2M | 838.0K | 754.2K | 882.3K | |
Short Term Investments | 2.0K | 1.9K | 13.3K | 17.4K | 15.7K | 14.9K | |
Property Plant Equipment | 440.2K | 637.7K | 953.3K | 599.2K | 539.3K | 759.3K | |
Non Current Liabilities Total | 1.2M | 33.3K | 558.9K | 381.6K | 343.5K | 400.6K | |
Accumulated Other Comprehensive Income | 8.8M | 11.0M | 11.5M | 6.5M | 7.5M | 4.4M | |
Other Liab | 979.2K | 8.9K | 170.5K | 152.3K | 175.2K | 128.6K | |
Net Tangible Assets | 13.0M | 21.5M | 11.3M | 7.5M | 8.7M | 10.6M | |
Capital Lease Obligations | 429.5K | 204.0K | 652.5K | 532.8K | 612.8K | 643.4K | |
Net Invested Capital | 13.1M | 21.5M | 16.4M | 11.2M | 12.8M | 12.5M | |
Net Working Capital | 13.8M | 20.8M | 10.9M | 7.2M | 8.3M | 10.9M | |
Capital Stock | 140.1M | 153.6M | 155.1M | 161.3M | 185.5M | 161.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 2.73 | Quarterly Revenue Growth (0.02) | Return On Assets (0.53) | Return On Equity (1.60) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.